Elanco Animal Health Incorporated — Cyborg Score 7/10
Strong
Pharmaceutical/Animal Health
Strategic Profile
Elanco is the third-largest animal health company in the world. The company's Innovation, Portfolio and Productivity (IPP) strategy is designed to guide the company's transformation to a sustainable growth company, delivering consistent mid-single digit organic constant currency revenue growth and adjusted EBITDA margin expansion. Elanco has 10+ major innovation projects with blockbuster potential in development, expecting approvals for 5-6 major differentiated assets from this pipeline between 2026 and 2031, representing an unprobabilized potential peak sales value of more than $2 billion.
Cyborg Score Rationale
With the share price at US$25.20 and a 1 year total shareholder return of 118.75%, recent price gains suggest momentum has been building. The company's robust innovation pipeline with 10+ major projects and $2+ billion peak sales potential from 2026-2031 provides significant upside. However, execution risks on new product launches and margin pressure remain.
Top Insights
Elanco is one of only two companies within the animal health industry that have monoclonal antibodies on the market today.
Company announced intended closure of German animal R&D facility with targeted reduction to manufacturing workforce and increased investment in Elanco Innovation Laboratories at its Indiana headquarters.
In February 2024, Elanco announced a strategic shift by selling its aquaculture business to Merck Animal Health for approximately $1.3 billion in cash.
Expects cost savings of approximately $25 million in 2026 and approximately $60 million in 2027 from restructuring initiatives.
Named Competitors
Zoetis — Leading global animal health company
Animal Health Division — Major competitor in pet and livestock health
Merck Animal Health — Global animal health and aquaculture provider
Recent Developments
(February 2026) Board transition announced with founding Chairman R. David Hoover and Dr. Deborah Kochevar not standing for re-election at May 2026 Annual Meeting
(December 2025) Elanco hosts first Investor Day in five years, details three-year outlook and announces 10+ major innovation projects in development
(December 2025) Announces restructuring charge of approximately $175 million with expected cash-based costs of approximately $130 million
(August 2024) Announces $130 million investment through 2026 for 25,000-square-foot expansion of biologics manufacturing facility in Kansas
Open the full interactive Elanco Animal Health Incorporated report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.